Agreement - January 4, 2023
Orion and Amneal enter strategic partnership
Orion Corporation has signed a long-term license agreement with Amneal Pharmaceuticals to commercialize Amneal’s generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include […]
Agreement - December 19, 2022
Nykode enters partnership with Richter-Helm BioLogics
Nykode Therapeutics has entered into a strategic manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious […]
Agreement - December 14, 2022
Novozymes and Chr Hansen merge
The two companies have entered into an agreement to create a global biosolutions partner through a statutory merger. The proposed combination of Novozymes and Chr. Hansen will create a group with a broad biological toolbox and a diversified portfolio across markets, the companies state. Together, the combined group will be equipped to stand stronger in addressing […]
Agreement - October 18, 2022
Mendus in agreement with Minaris Regenerative Medicine
Mendus has announced an agreement to enable the technology transfer for manufacturing of the company’s lead development program DCP-001 with Minaris Regenerative Medicine. DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial […]
Agreement - October 13, 2022
InfiCure Bio signs international agreements
The two agreements are with companies that are also active in the development of drugs for both liver and kidney fibrosis. “The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio,” says InfiCure Bio’s CEO, Sofia […]
Agreement - September 26, 2022
TILT Biotherapeutics signs new agreement with MSD
The Finnish company has signed a second clinical trial collaboration and supply agreement with MSD for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with Keytruda, MSD’s anti-PD-1 therapy. This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor […]
